NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
Clinical Trials
10 trialsNCT02360579 2026-03-25
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed
NCT05176470 2026-02-24
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05607095 2026-02-04
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07288203 2026-01-12
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT05640193 2025-09-12
LN-144
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03645928 2025-06-19
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT05398640 2025-06-17
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Iovance Biotherapeutics, Inc.
Available
NCT06190249 2025-06-05
LN-144
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown